Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News SkyePharma announces Flutiform study results

SkyePharma announces Flutiform study results

30th April 2008

SkyePharma has announced the results of a Phase III efficacy study to evaluate Flutiform (fluticasone and formoterol) as an asthma treatment for adult and adolescent patients.

The Flutiform study met is primary endpoints and compared the safety and efficacy of the drug combination when compared with the administration of fluticasone and formoterol twice daily.

According to SkyePharma, analysis of the study’s results indicated “significant differences” in favour of Flutiform when the levels of improvement in forced expiratory volume in the first second were compared.

“The preliminary results in this Phase III efficacy study represent a key step forward in the development of Flutiform,” said Frank Condella, chief executive officer of the pharmaceutical firm.

“We are looking forward to the top line results from the
remaining Phase III efficacy trials being announced in the coming months,” he added.

SkyPharma estimates that more than 50 million patients worldwide use an inhaled treatment to treat asthma and chronic bronchitis, as well as non-respiratory conditions such as chronic pain and diabetes.

We currently have 7 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.